The Fifth Tykeson Fellows Conference brought senior multiple sclerosis (MS) scientists together with nearly 100 young research and clinical fellows from the National Multiple Sclerosis Society, MS Society of Canada, and MS International Federation to promote collaboration, networking, and the sharing of research data with the goal of improving patients’ lives and developing…

The Multiple Sclerosis Society (MS Society) in the United Kingdom recently announced the investment of £1.98 million in new MS research. The 16 projects awarded funding through the MS Society’s 2015 grant round were thoroughly evaluated in a rigorous review process. In total, 58 projects applied for MS Society…

In a recent study published in the journal PLOS One, a team of researchers explored the differences in cognitive performance and magnetic resonance imaging (MRI) correlates of cognitive deficits in patients with relapsing-remitting multiple sclerosis (RRMS) and patients with primary progressive multiple sclerosis (PPMS) to underscore the importance…

Icometrix, a leader in magnetic resonance imaging (MRI) biomarkers for multiple sclerosis (MS), has recently announced a collaboration agreement with Novartis Pharma AG regarding MSmetrix – a measurement tool especially designed to assess brain volume and atrophy, as well as existing, new or enlarging brain lesions in MS patients. Monitoring…

Multiple sclerosis (MS) is a devastating, progressive disease of the nervous system. It is caused by loss of myelin, a fatty substance that wraps around nerve cells and allows them to conduct impulses and communicate. When myelin is lost, areas of damage called “lesions” result, which appear in the brain and…

Results from the BENEFIT11 trial indicate that early treatment with IFNB-1b leads to improvements in cognition and fatigue in the long-term, as well as sustained employment and favorable magnetic resonance imaging (MRI) outcomes, measured at the 11-year mark. Supported by Bayer HealthCare Pharmaceuticals, the study, titled “Long-term Impact of Early MS Treatment with…

A study from German researchers might help to determine how multiple sclerosis is assessed in treatment trials. Published February 6 in the journal PLoS ONE, the study is titled “Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts –…

Results from a Phase 3 clinical trial entitled “AVANCE” revealed promising clinical outcomes in patients with relapsing-remitting multiple sclerosis treated for one year with peg interferon beta-1a. The analysis was published in the journal BMC Neurology, in a study entitled “Effect of peg interferon beta-1a on MRI measures and…

A study entitled “Longitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple Sclerosis” published in the International Journal of MS Care reports that asymptomatic patients accompanied by Magnetic Resonance Images suggestive of…

Loss of myelin, the fatty protective sheath around nerve fibers, is a characteristic of multiple sclerosis (MS). A new magnetic resonance imaging (MRI) study by a team of researchers has determined that people with MS lose myelin in the gray matter of their brains, and that the amount of loss…

Magnetic resonance imaging (MRI) can predict responses to depression treatment in patients with multiple sclerosis (MS), according to Anthony Feinstein, Professor at the Department of Psychiatry of the Sunnybrook Health Sciences Centre & the University of Toronto. In the presentation “Depression in MS: Is brain imaging helpful?” at this…